Skip to main content

Advertisement

Table 3 Overview of the medication applied in the TAK cohort

From: TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study

Treatment At diagnosis Accumulated At last visit
cohort Early Late Early Late Early Late
Prednisolone p.o, n (%) 14 (70) 59 (86) 24 (100) 63 (91) 16 (67) 53 (77)
Metylprednisone i.v. n (%)a 0 17 (25)** 2 (8) 22 (32)** 0 1 (1.4)
Any DMARDs, n (%) 1 (4) 35 (51)*** 13 (54) 61 (88)*** 7 (29) 51 (74)***
 Methotrexate 1 (4) 28 (41)*** 11 (46) 55 (80)*** 5 (21) 42 (61)***
 Azathioprine 0 7 (10) 7 (29) 18 (26) 2 (8) 8 (12)
 Mycophenelate mofetil 0   1 (4) 3 (4) 0 1 (1.4)
 Cyclophosphamideb 2 (8) 6 (9) 4 (17) 7 (15) 0 0
Any biologic, n (%) 0 0 3 (13) 30 (44)* 3 (13) 23 (33)*
 Infliximab 0 0 2 (8) 29 (42)** 1 (4) 16 (23)*
 Etanercept 0 0 2 (8) 3 (4) 1 (4) 1 (1.4)
 Adalimumab 0 0 1 (4) 3 (4) 1 (4) 3 (4)
 Tocilizumab 0 0 1 (4) 5 (7) 0 3 (4)
Other medication, n (%)       
 Acetylsalicylic acid 2 (8) 32 (46)** 16 (67) 47 (68) 13 (57) 41 (59)
 Statin 1 (4) 16 (23) 16 (67) 34 (49) 13 (57) 32 (46)
  1. The early cohort (n = 24) included all patients diagnosed before year 2000, and the late cohort (n = 63) included patients diagnosed between 2000 and 2012. p.o. oral, i.v. intravenous. aUsually as 1000 mg daily for 3 consecutive days. bGiven as i.v. treatment 6 × 15 mg/kg. Significant differences between the cohorts are indicated: *p < 0.05, **p < 0.01, ***p < 0.001